Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Analysis of Median-dose Cyclophosphamide Treatment in 17 Patients with Refractory Myasthenia Gravis

WANG Jun-ling~*,YANG Yong,YANG Ming-shan,BU Bi-tao.~*Department of Neurology,Tongji Hospital,Huazhong University of Science and Technology,Wuhan 430030,China  
Objective: The efficacy,side-effects,and using method of median dose cyclophosphamide(MDC) therapy in 17 patients with refractory myasthenia gravis(RMG) were analyzed.Methods: Seventeen hospitalized patients with RMG treated with MDC have been retrospectively analyzed in terms of the influence of patients' ages at onset,sex,clinical types and the accompanying disorders on efficacy of cyclophosphamide therapy.Results:During a follow-up of 0.2-2 years,the total effectiveness rate was 91.3%,and the efficacy had no relation with age at onset,sex,clinical types,thymoma and thymectomy.The major side-effects included vomiting,myelosuppression,increased transient alanine aminotransferase and alopecie.Conclusion:The MDC therapy appeared to be an effective and safe therapy for RMG based on the comparison after the therapy.Further case-controlled,double-blinded studies of more patients are needed to evaluate the long-term outcome in refractory generalized MG patients.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved